G-401人肾癌Wilms细胞(STR鉴定正确)

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1348

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameG-401
SynonymsG401; G 401
AccessionBTCC-1348
Resource Identification InitiativeTo cite this cell line use: G-401 (BTCC-1348)
CommentsProblematic cell line: Misclassified. Originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line (PubMed=8382007; PubMed=30924592).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: H3K27me3 ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
Sequence variations
Genome ancestrySource: PubMed=30894373

Origin% genome


African2.48
Native American0.75
East Asian, North2.12
East Asian, South0.55
South Asian8.63
European, North29.24
European, South56.23
DiseaseRhabdoid tumor of the kidney (NCIt: C8715)
Rhabdoid tumor (ORDO: Orphanet_69077)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:



CVCL_QW55 (G-401 BAF47)CVCL_J252 (G-401-Luc)CVCL_L269 (G401.6)
Sex of cellMale
Age at sampling3M
CategoryCancer cell line
STR profileSource(s): ATCC; CCRID; Cosmic-CLP; ECACC; JCRB; PubMed=25877200

Markers:
AmelogeninX,Y
CSF1PO11,13
D2S133818,24
D3S135816,18
D5S81813
D7S82011,14
D8S117913,14
D13S3179,14
D16S53912
D18S5114
D19S43313,14
D21S1131,32.2 (CCRID)
31,32.2,33.2 (PubMed=25877200)
FGA24,27
Penta D10,11
Penta E7
TH018,9.3 (ATCC; CCRID; Cosmic-CLP; ECACC; JCRB)
9.3 (PubMed=25877200)
TPOX8,11 (ATCC; CCRID; Cosmic-CLP; ECACC; JCRB)
11 (PubMed=25877200)
vWA16

Run an STR similarity search on this cell line
Web pageshttps://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/g/cell-lines-detail-286.html
Publications

PubMed=8382007
Garvin A.J., Re G.G., Tarnowski B.I., Hazen-Martin D.J., Sens D.A.
The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney.
Am. J. Pathol. 142:375-380(1993)

PubMed=9671307; DOI=10.1038/28212
Versteege I., Sevenet N., Lange J., Rousseau-Merck M.-F., Ambros P.F., Handgretinger R., Aurias A., Delattre O.
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.
Nature 394:203-206(1998)

PubMed=10397258
Rousseau-Merck M.-F., Versteege I., Legrand I., Couturier J., Mairal A., Delattre O., Aurias A.
hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Cancer Res. 59:3152-3156(1999)

PubMed=10602515; DOI=10.1038/sj.onc.1203168
DeCristofaro M.F., Betz B.L., Wang W., Weissman B.E.
Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.
Oncogene 18:7559-7565(1999)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28945250; DOI=10.1038/ng.3958
Nakayama R.T., Pulice J.L., Valencia A.M., McBride M.J., McKenzie Z.M., Gillespie M.A., Ku W.L., Teng M.-X., Cui K.-R., Williams R.T., Cassel S.H., Qing H., Widmer C.J., Demetri G.D., Irizarry R.A., Zhao K.-J., Ranish J.A., Kadoch C.
SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nat. Genet. 49:1613-1623(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30924592; DOI=10.1002/pbc.27741
Pritchard-Jones K., Perotti D.
WARNING: G-401 and SK-NEP-1 cell lines are not Wilms tumor cell lines.
Pediatr. Blood Cancer 66:e27741.1-e27741.2(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resourcesCLO; CLO_0003434
MCCL; MCC:0000161
CLDB; cl1409
CCRID; 1101HUM-PUMC000034
Cell_Model_Passport; SIDM00856
Cosmic-CLP; 907299
DepMap; ACH-000096
IGRhCellID; G401
LINCS_LDP; LCL-1511
TOKU-E; 1303
Anatomy/cell type resourcesBTO; BTO:0002586
Biological sample resources4DN; 4DNSR6XERO32
BioSample; SAMN03470969
BioSample; SAMN03472819
BioSample; SAMN10987919
ENCODE; ENCBS062JBT
ENCODE; ENCBS432GBV
ENCODE; ENCBS629BMK
ENCODE; ENCBS659PBH
Cell line collections (Providers)ATCC; CRL-1441
ECACC; 87042204
JCRB; JCRB9065
Chemistry resourcesChEMBL-Cells; CHEMBL3308394
ChEMBL-Targets; CHEMBL613509
GDSC; 907299
PharmacoDB; G401_374_2019
PubChem_Cell_line; CVCL_0270
Encyclopedic resourcesWikidata; Q54835347
Experimental variables resourcesEFO; EFO_0002179

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部